About: RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $0.42 (-7.23%)
RDHL NASDAQ Redhill Biopharma Ltd
Redhill Biopharma Ltd share price
Atividade de preço de RDHL
Último preço
$ 0,420
Variação (24h)
-0,03 USD (7,23%)
Volume
236.40K
Volume (média 4 sem.)
-
Abertura
$ 0,46
Variação do dia
$ 0,41 - $ 0,47
Fechamento anterior
$ 0,46
Último negócio
22 Oct, 8:00 pm GMT+0
Atrasado
22 Oct, 8:00 pm GMT+0
RDHL price performance
Atrasado
22 Oct, 8:00 pm GMT+0
quote.marketSignals